By William S Pomat, Anita H J van den Biggelaar, Sandra Wana, Jacinta P Francis, Vela Solomon, Andrew R Greenhill, Rebecca Ford, Tilda Orami, Megan Passey, Peter Jacoby, Lea-Ann Kirkham, Deborah Lehmann, Peter C Richmond
Clinical Infectious Diseases, May 2019
PCV10 and PCV13 were studied head-to-head in a randomized controlled trial in Papua New Guinea in which 262 infants received 3 doses of PCV10 or PCV13 at 1, 2, and 3 months of age. Serotype-specific immunoglobulin G (IgG) concentrations, and pneumococcal and nontypeable Haemophilus influenzae (NTHi) carriage were assessed prevaccination and at 4 and 9 months of age. Infants were followed up for safety until 9 months of age.
Access article here